Magazine
Subscribe
Editorial
Media Kit
Talk to us

News : Health Dec 10, 2013 - 9:27:51 AM


The Genetics Research Center and the Institute of Living at Hartford Hospital Receive $1.25 Million Grant to Study Treatment of Depression

By Hartford Hospital





Font size: Small Big
Email this article
 Printer friendly page
Share this article:
facebook del.icio.us Yahoo! MyWeb Digg reddit Furl Blinklist Spurl
Buy the "As seen on" mug
Hartford, CT - The Genetics Research Center and the Institute of Living (IOL) at Hartford Hospital are at the forefront of using genetic testing results to determine whether such tests can improve the treatment of depression.

The Agency for Healthcare Research and Quality (AHRQ) has just awarded the Center and the Institute a $1.25 million grant to examine the impact of using genetic testing for the selection of medication for psychiatric inpatients on their length of stay in the hospital and their rates of readmission.

“This award truly catapults Hartford Hospital to the national stage of personalized medicine in clinical practice. This is the first AHRQ grant to be awarded to Hartford Hospital setting a new precedent,” said Harold Schwartz, M.D., Psychiatrist-in-Chief, Institute of Living at Hartford Hospital.

Treatment Background:
Most medicines used to treat depression are cleared from the body mainly by the liver. A gene called CYP2D6 helps determine how well the liver clears some, but not all drugs used to treat depression.

Differences in the CYP2D6 gene from person to person are common in both the healthy population and in hospitalized patients. Changes in the CYP2D6 gene affect how well the patient’s liver can clear drugs from the body. Some changes help the liver clear the drugs faster, which could render the drug ineffective, while others decrease or completely stop the liver’s ability to clear certain drugs, meaning that a drug may stay in the body longer, which cold predispose to side effects. Laboratory testing for a person’s CYP2D6 gene type can help researchers determine how fast the liver clears some drugs used to treat depression.

In this study, researchers are investigating whether prescribing drugs according to a patient’s CYP2D6 gene type makes a difference in treatment, length of hospital stay, and hospital readmissions. That data is being compared to patients for whom CYP2D6 gene type is used to help determine their clinical treatment, to patients treated without using the CYP2D6 gene type information.

“This research will assess whether knowing the CYP2D6 gene type leads to more effective treatment. If it does, this result might help decide which depression drugs are best for a patient,” said Gualberto Ruano, M.D., Principal Investigator, Director, Genetics Research Center, Hartford Hospital.

“We are hopeful that our continued research and our findings from this study will have a clinically meaningful impact on future methods to select the most appropriate and effective treatment for people with depression,” added Carolyn Hoban, DSc., VP Research, Hartford Hospital.

The study coincides with the publication of the fundamental manuscript and letter to the editor of Biomarkers in Medicine establishing the feasibility of the Program, Length of Psychiatric Hospitalization Correlated with CYP2D6 Functional Status in Inpatients with Major Depressive Disorder.


** “The project described was supported by Grant Number R01 HS022304 01. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Agency for Healthcare Research and Quality.”




© Copyright by StamfordPlus.com. Some articles and pictures posted on our website, as indicated by their bylines, were submitted as press releases and do not necessarily reflect the position and opinion of StamfordPlus.com, Stamford Plus magazine, Canaiden LLC or any of its associated entities. Articles may have been edited for brevity and grammar. Photos without a credit line are "contributed photos".




[an error occurred while processing this directive]




Note: We reserve the right to delete posts at any time if we decide that they are offensive or distasteful.
CURRENT HEADLINES:
Enjoy Easter on the Avenue at Morello Italian Bistro
Martin Appoints Ernie Orgera to Director of Operations
First Night Danbury seeks stories to share on its 25th anniversary
John T. and Jane A. Wiederhold Foundation Donates $250,000 for Mystic Aquarium’s New Research Center
The Warner Stage Company presents: All Shook Up


Top of Page










StamfordPlus.com is part of the Canaiden Online Media Network.
Stamford Plus Online | Norwalk Plus Online | Canaiden.com | Best of Norwalk | Best of Stamford | Hauterfly Magazine | SummerCampPlus.com

Copyright ©2005-2010 Canaiden,LLC All Rights Reserved.